交易 4D Molecular Therapeutics Inc - FDMT 差價合約
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.最新股票文章
期貨是什麼？一文看懂期貨合約運作、種類與香港交易入門
期貨是什麼？本文拆解期貨合約組成、保證金計算與常見類型（股指、商品、加密貨幣），並詳解香港恒指期貨玩法、開戶流程及風險管理，新手必讀入門教學。
10:57, 16 6月 2026
ETF是什麼？一文讀懂交易所買賣基金的運作、種類與投資方法
ETF是什麼？本文深入解析交易所買賣基金的運作原理、主要類型（指數、債券、主題、槓桿反向）、投資費用及香港/美股熱門ETF清單，幫助新手快速開始ETF投資。
10:21, 16 6月 2026
港人實戰：如何佈局 SpaceX IPO 前後的交易節奏
SpaceX以750億美元完成歷史性IPO，估值1.77萬億美元。深度解析港股CFD交易策略、供應鏈映射與恒生指數聯動，助投資者理解太空經濟相關市場動態。資本面臨風險。
08:58, 16 6月 2026
SpaceX上市首日收漲19%——IPO後如何交易SpaceX SPCX差價合約
SpaceX（SPCX）於2026年6月12日在納斯達克首次上市，開盤報150美元，收盤報160.95美元，較135美元的IPO發行價上漲19.2%。
08:23, 16 6月 2026
評級和評論
評級和評論
